| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/06/2024 | 14:28 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:HUGE | FSD Pharma Inc |
| 11/01/2024 | 19:10 | GlobeNewswire Inc. | GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case | NASDAQ:HUGE | FSD Pharma Inc |
| 05/01/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:HUGE | FSD Pharma Inc |
| 18/12/2023 | 18:31 | Edgar (US Regulatory) | Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] | NASDAQ:HUGE | FSD Pharma Inc |
| 22/09/2023 | 12:00 | GlobeNewswire Inc. | InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington | NASDAQ:HUGE | FSD Pharma Inc |
| 26/08/2023 | 00:16 | Business Wire | FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) | NASDAQ:HUGE | FSD Pharma Inc |
| 03/08/2023 | 12:00 | GlobeNewswire Inc. | InvestmentPitch Media Video Features FSD Pharma’s Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink | NASDAQ:HUGE | FSD Pharma Inc |
| 17/07/2023 | 23:00 | Business Wire | Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 | NASDAQ:HUGE | FSD Pharma Inc |
| 10/07/2023 | 13:30 | Business Wire | FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock | NASDAQ:HUGE | FSD Pharma Inc |
| 04/07/2023 | 16:00 | Business Wire | FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors | NASDAQ:HUGE | FSD Pharma Inc |
| 30/06/2023 | 14:30 | Business Wire | FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders | NASDAQ:HUGE | FSD Pharma Inc |
| 23/06/2023 | 12:00 | GlobeNewswire Inc. | InvestmentPitch Media Video Discusses FSD Pharma’s Granting of Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology to Celly Nutrition | NASDAQ:HUGE | FSD Pharma Inc |
| 21/06/2023 | 13:03 | PR Newswire (Canada) | DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION | NASDAQ:HUGE | FSD Pharma Inc |
| 20/06/2023 | 13:30 | Business Wire | FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology | NASDAQ:HUGE | FSD Pharma Inc |
| 25/05/2023 | 13:30 | Business Wire | FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors | NASDAQ:HUGE | FSD Pharma Inc |
| 16/05/2023 | 12:00 | GlobeNewswire Inc. | InvestmentPitch Media Video Discusses FSD Pharma’s Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement | NASDAQ:HUGE | FSD Pharma Inc |
| 12/05/2023 | 23:00 | Business Wire | FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution | NASDAQ:HUGE | FSD Pharma Inc |
| 11/05/2023 | 13:30 | Business Wire | FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari | NASDAQ:HUGE | FSD Pharma Inc |
| 10/05/2023 | 13:30 | Business Wire | FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort | NASDAQ:HUGE | FSD Pharma Inc |
| 08/05/2023 | 14:50 | Business Wire | FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 | NASDAQ:HUGE | FSD Pharma Inc |
| 17/04/2023 | 15:00 | Business Wire | FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis | NASDAQ:HUGE | FSD Pharma Inc |
| 12/04/2023 | 14:30 | Business Wire | FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 | NASDAQ:HUGE | FSD Pharma Inc |
| 01/04/2023 | 02:00 | Business Wire | FSD Pharma Announces Filing of Year-End 2022 Results | NASDAQ:HUGE | FSD Pharma Inc |
| 30/03/2023 | 14:30 | Business Wire | FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors | NASDAQ:HUGE | FSD Pharma Inc |
| 22/03/2023 | 13:30 | Business Wire | FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder | NASDAQ:HUGE | FSD Pharma Inc |
| 14/03/2023 | 13:30 | Business Wire | FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock | NASDAQ:HUGE | FSD Pharma Inc |
| 01/03/2023 | 12:00 | GlobeNewswire Inc. | InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board | NASDAQ:HUGE | FSD Pharma Inc |
| 28/02/2023 | 14:30 | Business Wire | Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board | NASDAQ:HUGE | FSD Pharma Inc |
| 21/02/2023 | 08:30 | Business Wire | FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum | NASDAQ:HUGE | FSD Pharma Inc |
| 15/02/2023 | 13:30 | Business Wire | FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements | NASDAQ:HUGE | FSD Pharma Inc |